Pulmonary Hypertension
❖ Pulmonary Arterial Hypertension (Idiopathic, Secondary, Autoimmune)
❖ ~100,000 patients in US/year
❖ 70% women with PAH
❖ Median PAH survival 3 years
❖ US PAH market size $5.3B annually
❖ PAH growing at a rate of ~4.9% per year
❖ Market Opportunity
❖ Current FDA-Approved Therapies for PAH
❖Therapies exist that improve QOL and slow progression
❖Curative therapies do not exist
❖No therapies exist that halt progression
